251 related articles for article (PubMed ID: 20651026)
1. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
[TBL] [Abstract][Full Text] [Related]
2. Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation.
Yamamoto E; Nakamura T; Kataoka K; Tokutomi Y; Dong YF; Fukuda M; Nako H; Yasuda O; Ogawa H; Kim-Mitsuyama S
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):258-63. PubMed ID: 21059340
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
4. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
[TBL] [Abstract][Full Text] [Related]
5. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition.
Yamamoto E; Dong YF; Kataoka K; Yamashita T; Tokutomi Y; Matsuba S; Ichijo H; Ogawa H; Kim-Mitsuyama S
Hypertension; 2008 Sep; 52(3):573-80. PubMed ID: 18678790
[TBL] [Abstract][Full Text] [Related]
6. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of loganin, iridoid glycoside from Corni Fructus, on hepatic and renal glucolipotoxicity and inflammation in type 2 diabetic db/db mice.
Yamabe N; Noh JS; Park CH; Kang KS; Shibahara N; Tanaka T; Yokozawa T
Eur J Pharmacol; 2010 Dec; 648(1-3):179-87. PubMed ID: 20826139
[TBL] [Abstract][Full Text] [Related]
8. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance.
Nomura M; Ishii H; Kawakami A; Yoshida M
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1030-8. PubMed ID: 19654286
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of 7-O-galloyl-D-sedoheptulose on oxidative stress and hepatic and renal changes in type 2 diabetic db/db mice.
Park CH; Noh JS; Yamabe N; Kang KS; Tanaka T; Yokozawa T
Eur J Pharmacol; 2010 Aug; 640(1-3):233-42. PubMed ID: 20447388
[TBL] [Abstract][Full Text] [Related]
11. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
[TBL] [Abstract][Full Text] [Related]
12. Increased oxidative stress in the streptozotocin-induced diabetic apoE-deficient mouse: changes in expression of NADPH oxidase subunits and eNOS.
Ding H; Hashem M; Triggle C
Eur J Pharmacol; 2007 Apr; 561(1-3):121-8. PubMed ID: 17292348
[TBL] [Abstract][Full Text] [Related]
13. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2010 Feb; 28(2):340-52. PubMed ID: 19864959
[TBL] [Abstract][Full Text] [Related]
14. Serum ornithine carbamyltransferase reflects hepatic damage in diabetic obese mice.
Murayama H; Ikemoto M; Hamaoki M
J Gastroenterol Hepatol; 2010 Feb; 25(2):413-9. PubMed ID: 19793175
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
Chang E; Kim L; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park CY
World J Gastroenterol; 2015 Jul; 21(25):7754-63. PubMed ID: 26167075
[TBL] [Abstract][Full Text] [Related]
16. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
18. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
[TBL] [Abstract][Full Text] [Related]
19. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice.
Howarth AG; Wiehler WB; Pannirselvam M; Jiang Y; Berger JP; Severson D; Anderson TJ; Triggle CR
J Pharmacol Exp Ther; 2006 Jan; 316(1):364-70. PubMed ID: 16249369
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
